These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25542065)

  • 1. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival.
    Chapiro J; Duran R; Lin M; Mungo B; Schlachter T; Schernthaner R; Gorodetski B; Wang Z; Geschwind JF
    Eur J Radiol; 2015 Mar; 84(3):424-430. PubMed ID: 25542065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
    Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
    Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
    Sahu S; Schernthaner R; Ardon R; Chapiro J; Zhao Y; Sohn JH; Fleckenstein F; Lin M; Geschwind JF; Duran R
    Radiology; 2017 Jun; 283(3):883-894. PubMed ID: 27831830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.
    Chapiro J; Duran R; Lin M; Schernthaner R; Lesage D; Wang Z; Savic LJ; Geschwind JF
    Eur Radiol; 2015 Jul; 25(7):1993-2003. PubMed ID: 25636420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
    Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
    Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization.
    Adam LC; Savic LJ; Chapiro J; Letzen B; Lin M; Georgiades C; Hong KK; Nezami N
    Clin Imaging; 2022 Sep; 89():112-119. PubMed ID: 35777239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Jung ES; Kim JH; Yoon EL; Lee HJ; Lee SJ; Suh SJ; Lee BJ; Seo YS; Yim HJ; Seo TS; Lee CH; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    J Hepatol; 2013 Jun; 58(6):1181-7. PubMed ID: 23395691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.
    Letzen BS; Malpani R; Miszczuk M; de Ruiter QMB; Petty CW; Rexha I; Nezami N; Laage-Gaupp F; Lin M; Schlachter TR; Chapiro J
    Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
    Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
    Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.
    Gillmore R; Stuart S; Kirkwood A; Hameeduddin A; Woodward N; Burroughs AK; Meyer T
    J Hepatol; 2011 Dec; 55(6):1309-16. PubMed ID: 21703196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
    Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
    Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis.
    Fleckenstein FN; Schernthaner RE; Duran R; Sohn JH; Sahu S; Marshall K; Lin M; Gebauer B; Chapiro J; Salem R; Geschwind JF
    Transl Oncol; 2016 Oct; 9(5):377-383. PubMed ID: 27641641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment.
    Assouline J; Cannella R; Porrello G; de Mestier L; Dioguardi Burgio M; Raynaud L; Hentic O; Cros J; Tselikas L; Ruszniewski P; Vullierme MP; Vilgrain V; Duran R; Ronot M
    Radiol Imaging Cancer; 2023 Jan; 5(1):e220051. PubMed ID: 36607243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
    Vogl TJ; Lahrsow M; Albrecht MH; Hammerstingl R; Thompson ZM; Gruber-Rouh T
    Eur J Radiol; 2018 May; 102():138-145. PubMed ID: 29685527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.
    Shim JH; Lee HC; Kim SO; Shin YM; Kim KM; Lim YS; Suh DJ
    Radiology; 2012 Feb; 262(2):708-18. PubMed ID: 22187634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
    Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
    Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
    Doemel LA; Chapiro J; Laage Gaupp F; Savic LJ; Kucukkaya AS; Petukhova A; Tefera J; Zeevi T; Lin M; Schlachter T; Jaffe A; Strazzabosco M; Patel T; Stein SM
    Eur Radiol; 2021 May; 31(5):2737-2746. PubMed ID: 33123796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.